Emmaus Life Sciences, Inc.SEC Filings
|
|
All SEC filings by Emmaus Life Sciences, Inc. (EMMA) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Aug 14, 2026 | |
| 10-Q | Quarterly report | View Diff | May 15, 2026 | |
| 10-K | Annual report | View Diff | Mar 30, 2026 | |
| 10-Q | Quarterly report | View Diff | Nov 14, 2025 | |
| 10-Q | Quarterly report | View Diff | Aug 14, 2025 | |
| 10-Q | Quarterly report | View Diff | May 15, 2025 | |
| 10-K | Annual report | View Diff | Apr 14, 2025 | |
| NT 10-K | Notice of late annual filing | Apr 1, 2025 | ||
| 10-Q | Quarterly report | View Diff | Nov 19, 2024 | |
| NT 10-Q | Notice of late quarterly filing | Nov 14, 2024 |
Events
| 8-K | Emmaus Life Sciences Reports Quarterly Financial Results | Aug 14, 2026 | ||
| 8-K | Emmaus Life Sciences Reports Quarterly Financial Results | May 15, 2026 | ||
| 8-K | Departure of Directors or Certain Officers | Apr 17, 2026 | ||
| 8-K | Departure of Directors or Certain Officers | Apr 14, 2026 | ||
| 8-K | Emmaus Life Sciences Reports Annual Financial Results | Mar 31, 2026 | ||
| 8-K | Entry Into a Material Definitive Agreement | Mar 4, 2026 | ||
| 8-K | Emmaus Life Sciences Announces Strategic Transaction | Dec 30, 2025 | ||
| 8-K | Entry Into a Material Definitive Agreement | Dec 22, 2025 | ||
| 8-K | Departure of Directors or Certain Officers | Dec 19, 2025 | ||
| 8-K | Emmaus Life Sciences Reports Quarterly Financial Results | Nov 14, 2025 |
Registrations and Prospectuses
| D | $235.00 K in Options, 1 Investor | Jan 31, 2023 | ||
| D | $34.00 Mm in Options, 3 Investors | Jan 20, 2023 | ||
| D | $220k in Equity, Sold $110k, 1 Investor | Jun 30, 2022 | ||
| S-8 | Registration of securities for employees | Dec 30, 2021 | ||
| D | $17m in Other Securities, Sold $1.92m, 10 Investors | Feb 16, 2021 | ||
| D/A | $3.84m in Options, Sold $3.84m, 18 Investors | Oct 9, 2020 | ||
| D/A | $3.68m in Options, Sold $3.68m, 18 Investors | Oct 7, 2020 | ||
| D | $3.68m in Options, 18 Investors | Oct 7, 2020 | ||
| D | $1.9m in Options, Sold $947.6k, 18 Investors | Aug 7, 2020 | ||
| 424B5 | Prospectus supplement for primary offering | Mar 3, 2020 |
Proxies
| DEF 14A | Definitive proxy | View Diff | Oct 31, 2022 | |
| PRE 14A | Preliminary proxy | View Diff | Oct 21, 2022 | |
| DEF 14A | Definitive proxy | View Diff | Oct 12, 2021 | |
| PRE 14A | Preliminary proxy | View Diff | Sep 30, 2021 | |
| DEF 14A | Definitive proxy | View Diff | Nov 2, 2018 | |
| PRE 14A | Preliminary proxy | View Diff | Oct 23, 2018 | |
| DEF 14A | Definitive proxy | View Diff | Mar 1, 2018 | |
| DEFA14A | Additional proxy soliciting materials | Aug 15, 2017 | ||
| DEF 14A | Definitive proxy | View Diff | Jul 27, 2017 | |
| PRE 14A | Preliminary proxy | View Diff | Apr 25, 2017 |
Other
| EFFECT | Notice of effectiveness | Jun 12, 2019 | ||
| CORRESP | Correspondence with SEC | Jun 11, 2019 | ||
| UPLOAD | Letter from SEC | May 30, 2019 | ||
| CORRESP | Correspondence with SEC | May 9, 2019 | ||
| UPLOAD | Letter from SEC | May 2, 2019 | ||
| UPLOAD | Letter from SEC | Feb 25, 2019 | ||
| EFFECT | Notice of effectiveness | Dec 24, 2018 | ||
| CORRESP | Correspondence with SEC | Dec 20, 2018 | ||
| UPLOAD | Letter from SEC | Dec 20, 2018 | ||
| EFFECT | Notice of effectiveness | Jul 2, 2018 |